Health Insurance (Section 3C Co-Dependent Pathology Services) Amendment Determination 2019 (Cth)
Health Insurance (Section 3C Co-Dependent Pathology Services) Amendment Determination 2019
I, ANGELA MIKALAUSKAS, delegate of the Minister for Health, make the following determination.
Dated 15 January 2019
Angela Mikalauskas
Acting Assistant Secretary
Diagnostic Imaging and Pathology Branch
Medical Benefits Division
Health Financing Group
Department of Health
Contents
1.Name 3
2.Commencement 3
3.Authority 3
4.Schedules 3
Schedule 1 – Amendment 4
Health Insurance (Section 3C Co-Dependent Pathology Services) Determination 2018
Name
This instrument is the Health Insurance (Section 3C Co-Dependent Pathology Services) Amendment Determination 2019.
Commencement
This instrument commences on 1 February 2019.
Authority
This instrument is made under subsection 3C(1) of the Health Insurance Act 1973.
Schedules
Each instrument that is specified in a Schedule to this instrument is amended or repealed as set out in the applicable items in the Schedule concerned, and any other item in a Schedule to this instrument has effect according to its terms.
Schedule 1 – Amendment
Health Insurance (Section 3C Co-Dependent Pathology Services) Determination 2018
1 Schedule 1 (at the end of the table)
Add:
| 73351 | A test of tumour tissue that is derived from a new sample from a patient with locally advanced (Stage IIIb) or metastatic (Stage IV) non-small cell lung cancer (NSCLC), who has progressed on or after treatment with an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI). The test is to be requested by a specialist or consultant physician, to determine if the requirements relating to EGFR T790M gene status for access to osimertinib under the Pharmaceutical Benefits Scheme are fulfilled. | 397.35 |
0
0
0